INSULIN RESISTANCE AND INTRAMYOCELLULAR LIPID CONTENT IN GLUCOSE INTOLERANCE

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。这个项目是两部分研究的第一部分。我们将通过口服葡萄糖耐量试验筛选高危参与者。葡萄糖耐量正常的个体将被要求参加我们的另一个GCRC SPID 0646。葡萄糖耐量受损的个体将被要求参与这个项目。本研究的主要目的是确定在糖耐量受损的个体中，噻唑烷类药物治疗后胰岛素敏感性的改善是否与心脏和骨骼肌脂质储存的减少有关。该研究已获得FDA的IND豁免。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This project is the initial segment of a two-part study. We will screen high-risk participants with an oral glucose tolerance test. The individuals with normal glucose tolerance will be asked to participate in our other GCRC SPID 0646. The individuals with impaired glucose tolerance will be asked to participate in this project. The primary objective of this investigation is to determine whether the improvement of insulin sensitivity following treatment with a thiazolidine drug is associated with reduced lipid stores in cardiac and skeletal muscle in individuals with impaired glucose tolerance. This study has received an exemption for IND from the FDA.